Portage Biotech Inc. files Form 6-K detailing Nasdaq's acceptance of its compliance plan. Key insights on financial health and operational status included.
On January 6, 2025, Portage Biotech Inc. re-launches Cyncado Therapeutics™ with CEO Peter Molloy, focusing on adenosine receptor antagonists. Key insights from the Form 6-K.
Discover key insights from Portage Biotech Inc.'s Form 6-K filed on Dec 17, 2024, detailing their LOI with Immunova for iOx Therapeutics acquisition, signaling potential growth.